Literature DB >> 2413295

Suppression of ventricular arrhythmias after coronary artery ligation by pinacidil, a vasodilator drug.

M J Kerr, R Wilson, R G Shanks.   

Abstract

Pinacidil, a new vasodilator compound, has been shown to lower blood pressure in animals and humans by a direct vasodilator effect. We have studied the effects of pinacidil on experimental cardiac arrhythmias in dogs. Pinacidil did not exhibit antiarrhythmic activity on ouabain-induced arrhythmias. In contrast, verapamil had minor antiarrhythmic activity on the ouabain arrhythmia, restoring sinus rhythm in one-third of the dogs studied. Pinacidil suppressed the arrhythmia present 22-24 h after coronary artery ligation at doses which produced a significant reduction in mean arterial pressure. The antiarrhythmic action of pinacidil was not modified by pretreatment with propranolol but appeared to be blunted by the infusion of the alpha-agonist, phenylephrine. Other hypotensive agents, hydralazine and sodium nitroprusside, although producing similar reductions in mean arterial pressure to pinacidil, did not exhibit a consistent antiarrhythmic action in dogs 22-24 h after coronary artery ligation. The calcium antagonist verapamil did not display antiarrhythmic activity on this model. The mechanisms by which pinacidil exerted an antiarrhythmic action have not yet been elucidated. The results of the present study suggest that further studies with pinacidil on myocardial infarct size, myocardial perfusion, and experimental cardiac arrhythmias would be advantageous.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2413295     DOI: 10.1097/00005344-198509000-00010

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

Review 1.  Electrophysiologic effects of potassium channel openers.

Authors:  W Haverkamp; M Borggrefe; G Breithardt
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

2.  Actions of pinacidil on membrane currents in canine ventricular myocytes and their modulation by intracellular ATP and cAMP.

Authors:  G N Tseng; B F Hoffman
Journal:  Pflugers Arch       Date:  1990-01       Impact factor: 3.657

Review 3.  Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  H A Friedel; R N Brogden
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

Review 4.  Pinacidil. Preclinical investigations.

Authors:  I Ahnfelt-Rønne
Journal:  Drugs       Date:  1988       Impact factor: 9.546

5.  Double-blind comparator trials with pinacidil, a potassium channel opener.

Authors:  J T Callaghan; M R Goldberg; R Brunelle
Journal:  Drugs       Date:  1988       Impact factor: 9.546

6.  Effects of pinacidil on guinea-pig isolated perfused heart with particular reference to the proarrhythmic effect.

Authors:  R Padrini; S Bova; G Cargnelli; D Piovan; M Ferrari
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

7.  Effects of cromakalim or glibenclamide on arrhythmias and dispersion of refractoriness in chronically infarcted in anesthetized dogs.

Authors:  A J D'Alonzo; J C Sewter; R B Darbenzio; T A Hess
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-08       Impact factor: 3.000

Review 8.  Modulation of ischemia by regulation of the ATP-sensitive potassium channel.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

Review 9.  Role of ATP-sensitive K+ channel current in ischemic arrhythmias.

Authors:  A A Wilde
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

10.  The effects of ATP-dependent potassium channel opener; pinacidil, and blocker; glibenclamide, on the ischemia induced arrhythmia in partial and complete ligation of coronary artery in rats.

Authors:  Selçuk Yaşar; Ömer Bozdoğan; Salih Tunç Kaya; Hayriye Soytürk Orallar
Journal:  Iran J Basic Med Sci       Date:  2015-02       Impact factor: 2.699

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.